Prospects for reducing and refining the use of dogs in the regulatory toxicity testing of pharmaceuticals

Abstract

A workshop was held to critically discuss the need for a non-rodent species and the role of the dog in regulatory toxicity testing of pharmaceuticals; to discuss opportunities to reduce and refine the use of dogs in preclinical toxicology; and to identify a number of specific recommendations which could be feasibly achieved to move the process forward. To facilitate a preliminary evaluation of the contribution of dog studies to the risk assessment process, anonymised, unpublished data were provided from fully evaluated, repeat dose toxicity studies in the rat and dog. Results ofthe International Life Sciences Institute (ILSI) Human Toxicity Project were also presented and discussed. Analysis of the data demonstrated that the dog can provide additional toxicity information, which, in some cases, was shown to be predictive for humans. Discussions indicated that there is potential for achieving a reduction in dog use and several possible approaches were identified. To further the progress of this initiative, there is a need to collate the results of pharmacology, toxicology, and clinical studies to address some of the proposed approaches. One of the outcomes of the workshop will be the establishment of a steering group to co-ordinate data collation for further analysis.

Keywords

dog regulatory toxicology reduction refinement three Rs pharmaceutical

References

1 Broadhead CL , Jennings M , Combes RD . A Critical Evaluation of the Use of Dogs in the Regulatory Toxicity Testing of Pharmaceuticals. FRAME, Nottingham, UK , 1999, 106-106 pp.

2 Bonser GM . How valuable the dog? Food Cosmet Toxicol 1968; 6: 349-352 .

3 Heywood R . Target organ toxicity . Toxicol Lett 1981; 8: 349-358 .

4 Heywood R . Target organ toxicity II . Toxicol Lett 1983; 18: 83-88 .

5 Falahee KJ , Rose CS , Seiffied HE , Sawhney D . Alternatives in toxicity testing. In: A.M. Goldberg (Ed.), Alternative Methods in Toxicology, Product Safety Evaluation, Vol. 1. Mary Ann Liebert, New York , 1983, pp.139-162.

6 Lumley CE , Walker SR . The value of chronic animal toxicology studies of pharmaceutical compounds: a retrospective analysis . Fundam Appl Toxicol 1985; 5: 1007-1024 .

7 Lumley CE , Walker SR . A critical appraisal of the duration of chronic animal toxicity studies . Regul Toxicol Pharmacol 1986; 6: 66-72 .

8 Lumley CE , Walker SR . The questionable value of longterm animal toxicology studies — a regulatory dilemma . Arch Toxicol 1986; 59: 237-239 .

9 Appelman LM , Feron VJ . Significance of the dog as “second animal species” in toxicity testing for establishing the lowest “no-toxic-effect level” . J Appl Toxicol 1986; 6: 271-279 .

10.

10 Speid L. Safety assessment of medicines. PhD Thesis, University of Wales, Cardiff, 1991, 280 pp.

11.

11 Lumley CE , Parkinson C , Walker SR . An international appraisal of the minimum duration of chronic animal toxicity studies . Hum Exp Toxicol 1992; 11: 155-162 .

12.

12 Contrera JF , Aub D , Barbehenn E , Belair E et al. A retrospective comparison of the results of six-and twelve-month non-rodent toxicity studies . Adverse Drug React Toxcol Rev 1993; 12: 63-76 .

13.

13 Igarashi T . A review of the Japanese Pharmaceutical Manufacturers Association database currently established to examine retrospectively the value of long-term animal toxicity studies . Adverse Drug React Toxicol Rev 1993; 12: 35-52 .

14.

14 Lumley CE , Parkinson C , Walker SR . A retrospective comparison of the results of six-and twelve-month non-rodent toxicity studies . Adverse Drug React Toxicol Rev 1993; 12: 53-61 .

15.

15 Parkinson C , Grasso P . The use of the dog in toxicity tests on pharmaceutical compounds . Hum Exp Toxicol 1993; 12: 99-109 .

16.

16 Zbinden G . The concept of multispecies testing in industrial toxicology . Regul Toxicol Pharmacol 1993; 17: 85-94 .

17.

17 Parkinson C , Lumley CW , Walker SR . The value of information generated by long-term toxicity studies in the dog for the non-clinical safety assessment of pharmaceutical compounds . Fundam Appl Toxicol 1995; 25: 115-123 .

18.

18 DeGeorge JJ , Meyers LL , Takahashi M , Contrera JF . The duration of non-rodent toxicity studies for pharmaceuticals . Toxicol Sci 1999; 49: 143-155 .

19.

19 Anon COSTART . Coding Symbols for Thesaurus of Adverse Reaction Terms, Fifth Edition. Gov't Reports Announcements and Index, Issue 22. FDA, Rockville, MD, USA , 1995.

20.

20 Clark B , Smith DA , Eason CT , Parke DV . Metabolism and excretion of a chromone carboxylic acid (FPL 52757) in various animal species . Xenobiotica 1982; 12: 147-153 .

21.

21 Olson HM , Betton G , Robinson D , Thomas K et a1. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Appl Pharmacol, submitted .

22.

22 ICH . Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals: recommended for adoption at step 4 of the ICH process on 16 July 1997 by the ICH Steering Committee. ICH , 1997, 7-7 pp.

23.

23 ICH . Preclinical safety evaluation of biotechnology derived pharmaceuticals: recommended for adoption at step 4 of the ICH process on 16 July 1997 by the ICH Steering Committee. ICH , 1997, 9-9 pp.

24.

24 Barker J , Garner RC . Biomedical applications of accelerator mass spectrometry isotope measurements at the level of the atom . Rapid Commun Mass Spectrom 1999; 13: 285-293 .

25.

25 Lumley C , van Cauteren H . Harmonisation of international toxicity testing guidelines for pharmaceuticals: contribution to refinement and reduction in animal use. EBRA Bull November 1997; 4-9. tib